Clinical trials · New York
Lung Cancer (Diagnosis) clinical trials in New York
We’re tracking 126 recruiting lung cancer (diagnosis) studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT06863233RecruitingPhase 1
Immune cell imaging study for people with lung cancer
This study uses an imaging method to look at certain immune cells (CD8+ T cells) in people with advanced non-small cell lung cancer who are about to receive a new cell therapy. It helps researchers understand how the immune system responds during treatment.
Commack, New YorkAges 18 years+ - NCT06869447Recruiting
Better Breathing After Lung Cancer Treatment
This study looks at breathing exercises for people who have finished treatment for early-stage lung cancer. You'll be asked to give a blood sample at home and do breathing training to see if it helps your recovery.
Buffalo, New YorkAges 18 years+ - NCT07287085Recruiting
Increasing lung cancer screening in emergency patients
This study tests a program to help emergency department patients get screened for lung cancer. If you smoke or used to smoke, the study will see if a text message reminder can help you schedule a screening test.
Rochester, New YorkAges 50–80 - NCT07323732RecruitingPhase 2
BIO 300 and radiation for lung cancer with lung scarring
This trial tests if adding BIO 300 to chest radiation is safe and helps people who have both non-small cell lung cancer (early stage) and interstitial lung disease (scarring of the lungs). It aims to find better treatment options for this specific group.
Uniondale, New YorkAges 18 years+ - NCT06060613RecruitingPhase 1/Phase 2
OBX-115 cell therapy for advanced melanoma or lung cancer
This trial tests an experimental cell therapy called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has not responded to standard treatments. The therapy uses your own immune cells to fight the cancer. The study aims to see if it is safe and effective.
New York, New YorkAges 18 years+ - NCT05361174RecruitingPhase 1/Phase 2
Testing an IOV-4001 infusion for advanced melanoma or lung cancer
This trial studies how well and how safely an infusion called IOV-4001 works in adults with advanced melanoma or non-small-cell lung cancer that cannot be removed with surgery. It also aims to see what side effects occur and whether the treatment can help control the cancer.
New York, New YorkAges 18–70 - NCT06582017RecruitingPhase 1
Study of QXL138AM for advanced solid tumors and multiple myeloma
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT07186296Recruiting
Emerald blood test study for new cancer diagnosis
This study is testing a blood test that looks for signs of lung, breast, colorectal, pancreatic, or ovarian cancer. If you have just been told you might have one of these cancers and haven't started treatment yet, this study may be an option to help learn more about your cancer from a simple blood draw.
Albany, New YorkAges 45 years+ - NCT06203210RecruitingPhase 3
Study of a new drug for relapsed small cell lung cancer
This study tests a new drug, ifinatamab deruxtecan, against the doctor's choice of standard treatments for people with extensive-stage small cell lung cancer that has returned after initial platinum-based chemotherapy. The goal is to see if the new drug works better and if it might be a new option for you.
Lake Success, New YorkAges 18 years+ - NCT06007937RecruitingPhase 1/Phase 2
Lorlatinib combined with ramucirumab for ALK lung cancer
This trial tests a combination of two targeted drugs, lorlatinib and ramucirumab, for people with ALK-positive lung cancer. It may be a new option if you have not had treatment yet or if a previous ALK medicine stopped working.
Commack, New YorkAges 19 years+ - NCT05098132RecruitingPhase 1/Phase 2
STK-012 drug for advanced lung cancer and other tumors
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
Lake Success, New YorkAges 18 years+ - NCT06858813RecruitingPhase 1
ABBV-324 for advanced liver or lung cancer
This study tests an experimental IV drug (ABBV-324) for adults with advanced liver cancer (HCC) or advanced squamous lung cancer (LUSC). It aims to see if the drug is safe and whether it can help control the disease.
New York, New YorkAges 18 years+ - NCT07531095RecruitingPhase 1
Combination drug trial for small cell lung cancer
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
New York, New YorkAges 18–99 - NCT07365319RecruitingPhase 2/Phase 3
New drug combo for stage 4 lung cancer
This trial tests a new drug called EIK1001 combined with standard immunotherapy (pembrolizumab) and chemotherapy for people with stage 4 non-small cell lung cancer who have not been treated before. The goal is to see if adding EIK1001 helps shrink tumors more than the current standard treatment.
Mineola, New YorkAges 18 years+ - NCT07249372RecruitingPhase 2
DRP-104 for a specific type of advanced lung cancer
This trial tests a new drug, DRP-104, for people with advanced non-small cell lung cancer that has a change in the NFE2L2 or KEAP1 genes. It is for people whose cancer has gotten worse after standard treatments like chemotherapy and immunotherapy.
New York, New YorkAges 18 years+ - NCT03851445RecruitingPhase 2/Phase 3
Lung cancer screening trial using tumor and blood test results
This trial helps sort people with previously treated lung cancer into the best next treatment options by using new tumor tissue (and sometimes blood) test results. It may help you get matched to therapies based on features like PD-L1 and other biomarkers.
The Bronx, New YorkAges 18 years+ - NCT05538130RecruitingPhase 1
Study medicine for BRAF-mutated advanced solid tumors
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
Brewster, New YorkAges 16 years+ - NCT07462377RecruitingPhase 1
Testing EPI-326 for EGFR-mutant lung and head & neck cancers
This trial tests a new drug, EPI-326, in people with advanced lung or head & neck cancers that have certain EGFR changes. The goal is to see if it is safe and may help shrink the cancer.
Lake Success, New YorkAges 18 years+ - NCT03191149RecruitingPhase 2
Osimertinib for lung cancer with an EGFR exon 20 change
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
Buffalo, New YorkAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
The Bronx, New YorkAges 18 years+ - NCT07288177RecruitingPhase 2
A study of Rina-S for people with non-small cell lung cancer
This trial tests a new drug called Rina-S for people with non-small cell lung cancer that has spread or can't be removed by surgery. It aims to see if the drug can shrink tumors and how safe it is.
Albany, New YorkAges 18 years+ - NCT04614103RecruitingPhase 2
Immune cell therapy for advanced lung cancer after chemotherapy
This trial studies LN-145, a treatment made from your own immune cells, for metastatic (stage IV) non-small-cell lung cancer. It may help shrink tumors after your cancer has progressed despite standard first-line chemotherapy and immunotherapy.
New York, New YorkAges 18–70 - NCT06712316RecruitingPhase 2/Phase 3
Testing a new drug combo for advanced lung cancer
This trial tests a new drug called BNT327 combined with chemotherapy and other treatments for people with advanced non-small cell lung cancer (NSCLC) who have not had any prior treatment. The goal is to see if this combination is safe and works better than current options.
Stony Brook, New YorkAges 18 years+
Where these studies are running in New York
Institutions with a site for the recruiting lung cancer (diagnosis) studies listed above.
- Memorial Sloan Kettering Cancer Center · 10 studies
- Memorial Sloan Kettering Nassau · 5 studies
- NYU Langone Health · 5 studies
- Columbia University Irving Medical Center · 4 studies
- Memorial Sloan Kettering Commack · 4 studies
- Memorial Sloan Kettering Cancer Center - Westchester · 3 studies
- Montefiore Medical Center · 3 studies
- Roswell Park Cancer Institute · 3 studies
What taking part in a lung cancer (diagnosis) study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lung Cancer (Diagnosis) trials in other states
Common questions
- Are there lung cancer (diagnosis) clinical trials in New York?
- Yes. We're currently tracking 126 recruiting lung cancer (diagnosis) studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer (diagnosis) study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer (diagnosis) trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer (diagnosis) studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.